Retinal Imaging for Cognitive Impairment Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to detect cognitive impairment, such as that related to Alzheimer's disease, and monitor disease progression, particularly through the detection of pericytes, PDGFR-β, LRP-1, or combinations thereof in the retina.
Innovation Solution
A method involving obtaining retinal images and detecting decreases in pericytes, PDGFR-β, LRP-1, or combinations thereof using advanced ophthalmic imaging techniques such as adaptive optics, optical coherence tomography angiography, and other imaging modalities to diagnose cognitive impairment and monitor its progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If advanced ophthalmic imaging techniques (adaptive optics, OCTA) are used to detect retinal markers, then measurement precision of pericytes/PDGFR-β/LRP-1 is improved, but device complexity increases
Solution Approach 1:
The patent uses the retina as an intermediary tissue to detect cerebral vascular pathology. By imaging retinal pericytes and PDGFR-β expression, the system indirectly detects markers of cognitive impairment and Alzheimer's disease without requiring direct brain imaging, thus achieving high measurement precision with manageable device complexity
Solution Approach 2:
The patent exploits the structural and functional similarities between the blood-retina barrier and the blood-brain barrier. Retinal vessels serve as a accessible copy or model of cerebral vasculature, allowing detection of vascular pathology through retinal imaging that mirrors what would be found in brain tissue
2Ease of operation
If retinal imaging is used to detect cognitive impairment, then ease of operation is improved, but measurement precision of cerebral pathology may worsen due to indirect detection
Solution Approach 1:
The patent establishes that retinal imaging serves multiple functions: it detects pericyte loss, PDGFR-β expression changes, LRP-1 levels, and correlates these with cognitive impairment stages. This multi-functional approach allows a single accessible imaging modality to provide comprehensive diagnostic information
Solution Approach 2:
The patent employs longitudinal retinal imaging to track changes in pericyte and PDGFR-β levels over time, providing feedback on disease progression. This temporal feedback loop enhances measurement precision by comparing baseline and follow-up images to detect subtle changes associated with cognitive decline
Data Source
AI summary
The present invention describes a method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. The method involves the detection of pericyte loss and deficiency in PDGFRβ, alone or in combination with retinal vascular Aβ deposits. The method also involves detecting an alteration in blood-retinal barrier (BRB) cell tight junction.